Back to Search Start Over

A Case of Brachial Lymph Node Recurrences after the Resection of Locally Advanced Breast Cancer.

Authors :
Onishi K
Watanuki R
Yokoe T
Iwatani T
Yamauchi C
Onishi T
Source :
Case reports in oncology [Case Rep Oncol] 2022 Aug 30; Vol. 15 (2), pp. 738-744. Date of Electronic Publication: 2022 Aug 30 (Print Publication: 2022).
Publication Year :
2022

Abstract

We present a case of two recurrences in the brachial lymph nodes after initial resection, which was performed for radical cure. A 66-year-old woman was diagnosed with left breast cancer T4bN3cM0 Stage IIIC and an immunohistochemistry assay showed estrogen receptor (ER) positivity (5%), progesterone-receptor (PgR) positivity (1%), human epidermal growth factor receptor-2 (HER2) positivity (3+), and low Ki-67 (15%). After four courses of adriamycin and cyclophosphamide, followed by four courses of trastuzumab plus docetaxel, the patient underwent left mastectomy and axillary dissection. Postoperatively, she was diagnosed with breast cancer ypT1cN0M0, and trastuzumab and anastrozole were started. Postoperative irradiation was performed. Three years and 5 months after the initial breast cancer surgery, she had left brachial lymph node recurrence. It was resected, and tamoxifen was administered postoperatively. One year and 9 months after, she had another left brachial lymph node recurrence, and it was resected. She received radiation therapy to her upper limb and started taking exemestane. After 1 year and 3 months since the second recurrence surgery, there has been no recurrence. Our case suggests that the replacement of regional lymph nodes with tumor cells may result in the reconstruction of lymph flow to the upper arm and the development of brachial lymph node metastasis. There are no reports of resection of the recurrent tumor in the brachial lymph node for curative treatment. Therefore, careful follow-up is important in the future.<br />Competing Interests: Tsuguo Iwatani received lecture fees from Eli Lilly, Asahi Kasei Medical, Novartis, and Pfizer. All remaining authors have no conflicts of interest to declare.<br /> (Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel.)

Details

Language :
English
ISSN :
1662-6575
Volume :
15
Issue :
2
Database :
MEDLINE
Journal :
Case reports in oncology
Publication Type :
Report
Accession number :
36157692
Full Text :
https://doi.org/10.1159/000525295